Federal Register - February 25, 2021
Versione di testo Cosa è?Dateas è un sito indipendente non affiliato a entità governative. La fonte dei documenti PDF che pubblichiamo qui è l'entità governativa indicata in ciascuno di essi. Le versioni in testo sono trascrizioni che realizziamo per facilitare l'accesso e la ricerca di informazioni, ma possono contenere errori o non essere complete.
Source: Federal Register
11548
Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices
Federal SUID/SIDS Workgroup members, SUID/SIDS stakeholders, clinical and maternal and child health professionals. These audiences may use the information collections to: 1
Develop new campaign messages, materials, and/or training curricula; 2
monitor and improve campaign activities; 3 make decisions about campaign activities; 4 inform current campaign activities; and 5 inform and/
or change practices and behaviors of program participants.
Examples of the types of information collections that could be included under this generic clearance include: Focus groups and key informant interviews
with parents/caregivers and/or health professionals to get feedback on distribution and outreach activities, and/or campaign messages; and Surveys with parents/caregivers and/or health professionals to: 1 Assess the usefulness of the new STS campaign materials, including print and on-line multi-media materials, 2 track outreach experiences of program participants, 3 assess training participants changes in knowledge related to safe infant sleep behavior and implementation of learned outreach and education methods, and 4 assess program participants resource needs.
The sub-studies for this generic clearance will be small in scale, designed to obtain results frequently and quickly to guide campaign development and implementation, inform campaign direction, and be used internally for campaign management purposes. NICHDs current scope and capacity for STS generic sub-studies is non-existent and this request would fill this gap.
OMB approval is requested for 3
years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 13,305.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Focus Groups
Interviews
Pre-/Post-Tests
Pre-/Post-Tests
Surveys
Tracking/Feedback Form
General Public
General Public
General Public
Health Professionals
Health Professionals
Health Educators
Total
Dated: February 12, 2021.
Jennifer M. Guimond, Project Clearance Liaison, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.
FR Doc. 202103870 Filed 22421; 8:45 am
National Institutes of Health Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Iovance Biotherapeutics, Inc. Iovance, headquartered in San Carlos, CA.
Jkt 253001
215
50
1,500
10,000
1,500
40
26,285
49,305
13,305
Only written comments and/or applications for a license which are received by the National Cancer Institutes Technology Transfer Center on or before March 12, 2021 will be considered.
DATES:
E0682018: Tethered Interleukin-15
and Interleukin-21
Notice.
17:04 Feb 24, 2021
1
1
15/60
15/60
30/60
1
Intellectual Property
National Institutes of Health,
VerDate Sep<11>2014
1
1
2
2
1
2
SUPPLEMENTARY INFORMATION:
HHS.
SUMMARY:
215
50
3,000
20,000
3,000
20
Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: 2402765484; Email:
andy.burke@nih.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
Average burden per response, in hours
ADDRESSES:
BILLING CODE 414001P
AGENCY:
Number of responses per respondent
Number of respondents
Form name
1. US Provisional Patent Application 62/628,454, filed February 9, 2018 E
06820180US01;
2. International Patent Application PCT/US2019/016975, filed February 7, 2019 E06820180PCT02;
3. Australian Patent Application 2019218785, filed August 7, 2020 E
06820180AU03;
4. Chinese Patent Application 201980012443.3, filed August 7, 2020
E06820180CN04;
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Total annual burden hours
5. European Patent Application 19709154.9, filed August 18, 2020 E
06820180EP05;
6. United States Patent Application 16/964,796, filed July 24, 2020 E068
20180US06; and 7. Canadian Patent Application 3,090,512, filed August 5, 2020 E068
20180CA07.
The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide, and the field of use may be limited to the following:
The use of the Licensed Patent Rights to develop, manufacture, distribute, sell, and use unselected whole autologous tumor infiltrating lymphocyte TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers. Specifically excluded from this Agreement are methods of generating or using selected subpopulations of TIL and the use of T
cell receptors isolated from TIL.
E0682018 is primarily directed to recombinant constructs for the coexpression of Interleukins-15 and 21
IL15 and 21. IL15 and IL21 have been reported to support the function of anti-tumor T cells; however, their
E:FRFM25FEN1.SGM
25FEN1
